Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Home
»
Target enrollment complete in Phase 1b trial of GT-02287 - Perspectives from Gain Therapeutics
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Related Posts
Target enrollment complete in Phase 1b trial of GT-02287
Parkinson’s News Today
Jul 07, 2025
Target enrollment complete in Phase 1b trial of GT-02287
Related Posts
Post navigation
Previous Post
Gain Therapeutics stock advances as Phase 1b trial enrollment exceeds expectations
Next Post
Gain Therapeutics announces pricing of $7M public offering
Latest Articles
Clear Filters
January 26, 2026
5 Investigational Therapies That Could Change the Parkinson’s Landscape
https://www.biospace.com/drug-development/5-investigational-therapies-that-could-change-the-parkinsons-landscape
Read More
January 13, 2026
Early trial data suggest GT-02287 may aid Parkinson’s symptoms
https://parkinsonsnewstoday.com/news/early-trial-data-suggest-gt-02287-aid-parkinsons-symptoms/
Read More
January 9, 2026
New data suggest enzyme modulator may slow Parkinson’s
https://longevity.technology/news/new-data-suggest-enzyme-modulator-may-slow-parkinsons/
Read More
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles